


# Taxonomy of Accelerated Coverage Pathways for Innovations (ACPIs)


December 2020



Source: Alira Health/ValueConnected analysis

# Taxonomy of Accelerated Coverage Pathways for Innovations (ACPIs)

December 2020



Note: <sup>1</sup> Are part of the Accelerated Access Collaborative, the umbrella department overseeing different programs, including 3 ACPI's' Swiss ACPIs not included in the taxonomy; ACPI in Wales to be added when more information is available.


























Source: Alira Health/ValueConnected analysis

# Taxonomy of Accelerated Coverage Pathways for Innovations (ACPIs)

December 2020

## Definitions

- **Utilization caps:** Limited amount of funding or number of individual patients to be treated with the technology
- **Fixed cost per patient:** Reimbursement is limited to a certain amount per patient (bundled payment)
- **Only with research:** All patients for a specific technology are reimbursed while the study is going on.
- **Only in research:** Only patients within the clinical study are reimbursed, with broader coverage determined on the success of the clinical study
- **Pay-for-performance:** These involve a MedTech company to refund to the payer financial or replacement stock if a patient does not achieve a specified target.
- **Conditional treatment continuation:** When collecting economic & clinical evidence, the payer can withdraw payment if the patient or patient population outcomes are not met

| Programs   |   | Quadrant    | Specifics   |
|--|---|-------------|---|
| Austria – Provisional/Analogous MEL Procedure Codes                        |    | Clinical    | Conditional treatment                                     |
| Belgium – Limited Clinical Application                                     |    | Performance | Utilization cap, only in Research, conditional treatment  |
| England – Artificial Intelligence in Health & Care Award England (phase 4) |    | Performance | Only in research  |
| England – Innovation and Technology Payment Program                        |    | Budget      | Utilization cap, fixed cost per patient                   |
| England – NHS Innovation Accelerator (NIA)                                 |    | Performance |   |
| England – MedTech Funding Mandate  |    | Performance | Program designed to support adoption; NICE supported ACPI |
| England – Rapid Uptake Products  |    | Performance | Program designed to support adoption; NICE supported ACPI |
| France – Hospital Clinical Research Program (PHRC)                         |    | Clinical    | Only in research  |
| France – Health Economic Research Program (PRME)                           |    | Performance | Only in research  |
| France – Forfait Innovation  |    | Performance | Only in research  |
| France – Référentiel des actes Innovants Hors Nomenclature (RIHN)          |    | Performance | Only with research, conditional treatment                 |
| France – Article 51 of Social Security law (2018 & 2019)                   |    | Performance | Only in research  |
| France – ETAPES Program  |   | Performance | Only in research, conditional treatment                   |
| Germany – 137e Trial Regulation  |  | Clinical    | Only in research  |
| Germany – 137h Trial Regulation  |  | Clinical    | Only in research  |
| Germany – NUB  |  | Budget      | Utilization cap or fixed cost per patient                 |
| Germany – Selective Contracts  |  | Performance | Pay-for-performance or conditional treatment              |
| Germany – Innovation Funds   |  | Clinical    | Only in research  |
| Germany – Digital Health Applications (DiGA)                               |  | Performance | Conditional treatment                                     |
| Netherlands – Innovations for Small-Scale Experiments                      |  | Performance | Pay-for-performance                                       |
| Netherlands – Promising Care   |  | Performance | Conditional treatment                                     |
| Portugal – Medical Device Reimbursement                                    |  | Budget      | Fixed cost per patient                                    |
| Scotland – IMTO Process from Health Technology                             |  | Performance |   |
| Spain – Supervised Use   |  | Performance | Only in research  |
| Spain – Monitoring Studies   |  | Performance | Only in research  |

Note: the Commissioning Through Evaluation is still officially accessible, however no new programs have been added, and many programs are dormant subject to further evidence  
Source: Alira Health/ValueConnected analysis